CN115299544A - Peony collagen ginseng composite peptide solid beverage and preparation method thereof - Google Patents
Peony collagen ginseng composite peptide solid beverage and preparation method thereof Download PDFInfo
- Publication number
- CN115299544A CN115299544A CN202210968122.4A CN202210968122A CN115299544A CN 115299544 A CN115299544 A CN 115299544A CN 202210968122 A CN202210968122 A CN 202210968122A CN 115299544 A CN115299544 A CN 115299544A
- Authority
- CN
- China
- Prior art keywords
- peptide
- solid beverage
- peony
- collagen
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 158
- 239000007787 solid Substances 0.000 title claims abstract description 88
- 235000013361 beverage Nutrition 0.000 title claims abstract description 87
- 235000006484 Paeonia officinalis Nutrition 0.000 title claims abstract description 52
- 241000208340 Araliaceae Species 0.000 title claims abstract description 51
- 102000008186 Collagen Human genes 0.000 title claims abstract description 51
- 108010035532 Collagen Proteins 0.000 title claims abstract description 51
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 51
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 51
- 229920001436 collagen Polymers 0.000 title claims abstract description 51
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 239000002131 composite material Substances 0.000 title claims abstract description 31
- 244000170916 Paeonia officinalis Species 0.000 title abstract 4
- 229920001184 polypeptide Polymers 0.000 claims abstract description 81
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 81
- 239000000203 mixture Substances 0.000 claims abstract description 68
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 9
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 9
- 241000283690 Bos taurus Species 0.000 claims abstract description 8
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 8
- 244000269722 Thea sinensis Species 0.000 claims abstract description 7
- 240000000691 Houttuynia cordata Species 0.000 claims abstract description 6
- 235000013719 Houttuynia cordata Nutrition 0.000 claims abstract description 6
- 244000179886 Moringa oleifera Species 0.000 claims abstract description 6
- 235000011347 Moringa oleifera Nutrition 0.000 claims abstract description 6
- 240000008042 Zea mays Species 0.000 claims abstract description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 6
- 235000005822 corn Nutrition 0.000 claims abstract description 6
- 241000736199 Paeonia Species 0.000 claims description 48
- 230000000694 effects Effects 0.000 claims description 32
- 239000000419 plant extract Substances 0.000 claims description 20
- 239000002994 raw material Substances 0.000 claims description 20
- 238000000605 extraction Methods 0.000 claims description 18
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 108090000145 Bacillolysin Proteins 0.000 claims description 12
- 108091005507 Neutral proteases Proteins 0.000 claims description 12
- 102000035092 Neutral proteases Human genes 0.000 claims description 12
- 108091005658 Basic proteases Proteins 0.000 claims description 11
- 108091005804 Peptidases Proteins 0.000 claims description 10
- 239000004365 Protease Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 241000196324 Embryophyta Species 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 4
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 4
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 4
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 4
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 4
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 4
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 4
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 4
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 4
- 240000000171 Crataegus monogyna Species 0.000 claims description 4
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 4
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 4
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 240000001949 Taraxacum officinale Species 0.000 claims description 4
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 4
- 244000126002 Ziziphus vulgaris Species 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 4
- 241000220317 Rosa Species 0.000 claims description 3
- 238000000498 ball milling Methods 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 230000009849 deactivation Effects 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 230000002255 enzymatic effect Effects 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000000413 hydrolysate Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 102000002322 Egg Proteins Human genes 0.000 claims description 2
- 108010000912 Egg Proteins Proteins 0.000 claims description 2
- 102000006395 Globulins Human genes 0.000 claims description 2
- 108010044091 Globulins Proteins 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- -1 compound amino acid Chemical class 0.000 claims description 2
- 235000013345 egg yolk Nutrition 0.000 claims description 2
- 210000002969 egg yolk Anatomy 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 2
- 229940013618 stevioside Drugs 0.000 claims description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 2
- 235000019202 steviosides Nutrition 0.000 claims description 2
- 229960003080 taurine Drugs 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 240000002547 Rosa roxburghii Species 0.000 claims 1
- 235000000640 Rosa roxburghii Nutrition 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 102
- 210000004369 blood Anatomy 0.000 abstract description 102
- 230000036772 blood pressure Effects 0.000 abstract description 52
- 235000000346 sugar Nutrition 0.000 abstract description 42
- 230000001603 reducing effect Effects 0.000 abstract description 32
- 238000013329 compounding Methods 0.000 abstract description 8
- 206010020772 Hypertension Diseases 0.000 abstract description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 4
- 201000001421 hyperglycemia Diseases 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 3
- 238000004321 preservation Methods 0.000 abstract 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 30
- 230000008859 change Effects 0.000 description 27
- 238000012360 testing method Methods 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 150000002632 lipids Chemical class 0.000 description 11
- 102000035195 Peptidases Human genes 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 210000004404 adrenal cortex Anatomy 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000005495 thyroid hormone Substances 0.000 description 2
- 229940036555 thyroid hormone Drugs 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 235000020937 fasting conditions Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The application relates to the technical field of solid beverages, in particular to a peony collagen ginseng composite peptide solid beverage and a preparation method thereof. The peony collagen ginseng composite peptide solid beverage is characterized by comprising a polypeptide composition and a solid beverage basic formula; the polypeptide composition is one or more of peony oligopeptide, bovine bone collagen peptide, ginseng peptide, corn stigma peptide, moringa oleifera leaf peptide, houttuynia cordata peptide and tea polypeptide. The purposes of assisting in reducing blood sugar, blood pressure and blood fat are achieved by adding the polypeptide composition and compounding the components, and the health-care tea is particularly suitable for health care and health preservation of people with hypertension, hyperglycemia and hyperlipidemia.
Description
Technical Field
The application relates to the technical field of solid beverages, in particular to a peony collagen ginseng composite peptide solid beverage and a preparation method thereof.
Background
Solid beverage, it is taking sugar, dairy products, egg products, plant extracts as the main material, add right amount of supplementary product or solid tablet that the auxiliary material is made into, in recent years, with the improvement of people's living standard and increase of the pressure of living, various sub-health problems also come along with, therefore have certain solid beverage of health function come into play.
In the related art, according to different selections of components such as plant extracts, the solid beverage with the health-care function mainly covers the aspects of invigorating stomach, promoting digestion, promoting blood circulation, warming stomach, nourishing, beautifying and the like, but the solid beverage for people with hypertension, hyperglycemia, hyperlipidemia and the like is not provided, so that the peony collagen ginseng composite peptide solid beverage capable of assisting in reducing blood sugar, blood pressure and blood fat and the preparation method thereof are urgently needed.
Disclosure of Invention
In order to endow the solid beverage with the effects of assisting in reducing blood sugar, blood pressure and blood fat and enable the solid beverage to be suitable for people with high blood sugar, high blood pressure and high blood fat so as to reduce the possibility of cardiovascular and cerebrovascular diseases such as coronary heart disease, myocardial infarction, cerebral apoplexy and the like, the application provides the peony collagen ginseng composite peptide solid beverage and the preparation method thereof.
In a first aspect, the application provides a peony collagen ginseng composite peptide solid beverage, which adopts the following technical scheme:
a peony collagen ginseng compound peptide solid beverage is characterized by comprising a polypeptide composition and a solid beverage basic formula; the polypeptide composition is one or more of peony oligopeptide, bovine bone collagen peptide, ginseng peptide, corn stigma peptide, moringa oleifera leaf peptide, houttuynia cordata peptide and tea polypeptide.
By adopting the technical scheme, all components in the used polypeptide composition can promote the secretion of thyroid hormone and insulin, inhibit the rise of cholesterol and regulate blood sugar through the characteristics of the polypeptide, thereby achieving the effects of assisting in reducing blood fat, blood sugar and blood pressure;
the multi-component polypeptide composition can further improve the effects of reducing blood fat, blood sugar and blood pressure by compounding, and the analysis reason is probably that the metabolism capability and the vascular toughness of the kidney of a human body are obviously improved due to the multi-component compounding, so that an environment which is not beneficial to causing the hypertension, the hyperlipidemia and the hyperglycemia is created.
Preferably, the dosage of the polypeptide composition and the solid beverage base formula is 1 (0.1-0.5) in weight ratio; the polypeptide composition comprises the following components in parts by weight:
5-8 parts of peony oligopeptide, 8-12 parts of bovine bone collagen peptide, 3-5 parts of ginseng peptide, 0-8 parts of corn stigma peptide, 0-3 parts of moringa oleifera leaf peptide, 0-3 parts of houttuynia cordata peptide and 0-15 parts of tea polypeptide.
By adopting the technical scheme, the polypeptide composition with the components and the proportion can exert the effects of promoting blood fat reduction, blood sugar reduction and blood pressure reduction through multi-component compounding, wherein peony oligopeptide, bovine bone collagen peptide and ginseng peptide are necessary basic formulas;
the reason for analyzing the polypeptide is probably that the polypeptide components can enter adrenal cortex and microvessels respectively, and the aim of improving the metabolic capability and the vascular toughness of human kidneys is fulfilled by dissolving intravascular microemboli, stimulating the adrenal cortex and improving the microcirculation system of the adrenal cortex.
Preferably, the extraction method of each component in the polypeptide composition is as follows:
a1, performing ball milling treatment on each polypeptide raw material to obtain a coarse material;
a2, placing the coarse material obtained in the step A1 in ethanol, adjusting the pH value of the solution to 7.0-7.5, adjusting the temperature to 48-52 ℃, and adding 0.2-0.5% of protease for enzymolysis for 2-3h;
and A3, finally, putting the enzymatic hydrolysate after the completion of the enzymolysis into boiling water for enzyme deactivation for 3-5min, then carrying out centrifugal treatment, and filtering and freeze-drying the obtained precipitate to obtain each component in the polypeptide composition.
By adopting the technical scheme, the polypeptide composition prepared by the extraction method has stable performance, higher active ingredient retention amount and most obvious improvement effect on kidney metabolic capability and vascular toughness;
in addition, the adopted polypeptide composition has excellent oxidation resistance, is easy to be absorbed by a human body, and is not easy to bring extra load to the human body, namely free radicals causing aging are not easy to generate due to stimulation when the polypeptide composition acts on blood vessels and kidneys.
Preferably, the protease consists of neutral protease and alkaline protease according to the weight ratio of 1 (0.1-0.2);
the enzyme activity of the neutral protease is 0.8AU/g;
the enzyme activity of the alkaline protease is 2.4AU/g.
By adopting the technical scheme, the polypeptide composition extracted by the protease has higher retention amount of active ingredients in the polypeptide composition and excellent oxidation resistance, so that the polypeptide composition can achieve the effects of assisting in reducing blood sugar, blood pressure and blood fat after being taken.
Preferably, the plant extract composition also comprises plant extract components, and the plant extract components are prepared from one or more of winter jujube, roxburgh rose, dandelion, chrysanthemum and hawthorn.
Preferably, the dosage of the plant extract component and the solid beverage basic formula is 1 (0.1-0.3) in weight ratio; the preparation raw materials of the plant extraction component comprise the following components in parts by weight:
5-8 parts of winter jujube, 10-15 parts of roxburgh rose, 2-3 parts of dandelion, 1-2 parts of chrysanthemum and 5-8 parts of hawthorn.
By adopting the technical scheme, the plant extract prepared from the raw materials can act on a human body to directly enhance the basic immunity of the human body, and can also act on the heart and blood vessels to play long-acting and lasting roles in reducing blood pressure and protecting the human body under the condition of continuously taking the plant extract for 1-3 months;
in addition, the adopted extraction raw materials are all green and natural, and have excellent oxidation resistance, so that the polypeptide composition is easy to absorb by a human body, is not easy to bring additional stimulation and load to the human body, and can supplement the polypeptide composition with short-term effect.
Preferably, the solid beverage base formula comprises the following components in percentage by weight:
1-10% of compound amino acid powder, 3-5% of sodium hyaluronate, 1-10% of taurine, 1-2% of L-lysine hydrochloride, 1-2% of glycine, 2-3% of stevioside, 20-30% of hydroxypropyl methyl cellulose and the balance egg yolk globulin powder.
By adopting the technical scheme, the solid beverage basic formula consisting of the components and the proportion can ensure the basic performances of hardness, disintegration, taste and nutrition supply of the solid beverage, has excellent combination compatibility with the polypeptide composition, and can promote the penetration and diffusion of the polypeptide composition after being taken.
In a second aspect, the application provides a using method of a peony collagen ginseng composite peptide solid beverage, which adopts the following technical scheme:
a use method of a peony collagen ginseng composite peptide solid beverage comprises the following specific steps:
s1, uniformly mixing the components in the raw materials with deionized water according to the weight percentage of 1 (3-5), heating to 50-60 ℃, and circularly homogenizing for 3-5 times to obtain mixed feed liquid;
s2, putting the mixed material liquid obtained in the step S1 into a spray freeze dryer, controlling the air inlet temperature to be 100-120 ℃, and controlling the air inlet flow rate to be 240-280m 3 And h, the air outlet temperature is 80-100 ℃, and the peony collagen ginseng composite peptide solid beverage can be prepared.
By adopting the technical scheme, the hardness, the disintegration rate and the water content of the finished product of the prepared peony collagen ginseng composite peptide solid beverage can be effectively controlled while the process time and the operation conditions are optimized.
In summary, the present application has the following beneficial effects:
1. the polypeptide composition used in the application can obviously improve the metabolic capability and the vascular toughness of the kidney of a human body through the characteristics and the compounding of the polypeptide composition per se 22, so that an environment which is not beneficial to causing three highs is created, and then the solid beverage is endowed with the effects of assisting in reducing blood fat, blood sugar and blood pressure;
2. the plant extract can act on a human body to directly enhance the basic immunity of the human body, and can also act in a synergistic manner on the polypeptide composition, so that the plant extract can act on the cardiovascular system for a long time and a long time to play roles in reducing the blood pressure and protecting the cardiovascular system;
3. according to the preparation process, the time and conditions are remarkably optimized, the prepared peony collagen ginseng composite peptide solid beverage is stable in performance, excellent in activity and oxidation resistance, and the quality of finished products such as hardness, disintegration rate and water content is effectively controlled.
Detailed Description
The present application will be described in further detail with reference to examples, but the raw materials used in the examples of the present application are commercially available raw materials.
Preparation example
Preparation examples 1 to 6
A polypeptide composition, the components and their corresponding weights of which are shown in the following table, is prepared by the following preparation method:
a1, performing ball milling treatment on each polypeptide raw material to obtain a coarse material;
a2, placing the crude material obtained in the A1 into 95% ethanol water solution according to the volume ratio of 1;
wherein the protease is neutral protease with enzyme activity of 0.8AU/g;
and A3, finally, putting the enzymatic hydrolysate subjected to enzymolysis in boiling water for 5min for enzyme deactivation, then performing centrifugal treatment, and filtering and freeze-drying the obtained precipitate to obtain the components of the polypeptide composition.
Table (b): each component and its weight (kg) in preparation examples 1 to 6
Preparation example 7
A polypeptide composition, which is different from preparation example 1 in that protease is composed of neutral protease and alkaline protease at a weight ratio of 1; the enzyme activity of the neutral protease is 0.8AU/g; the enzyme activity of the alkaline protease is 2.4AU/g.
Preparation example 8
A polypeptide composition, which is different from preparation example 1 in that protease is composed of neutral protease and alkaline protease at a weight ratio of 1; the enzyme activity of the neutral protease is 0.8AU/g; the enzyme activity of the alkaline protease is 2.4AU/g.
Preparation example 9
A polypeptide composition, which is different from preparation example 1 in that protease is composed of neutral protease and alkaline protease at a weight ratio of 1; the enzyme activity of the neutral protease is 0.8AU/g; the enzyme activity of the alkaline protease is 2.4AU/g.
Preparation examples 10 to 15
A plant extract, the components of which and the corresponding weights of the raw materials are shown in the following table, is obtained by extraction through the following steps:
a1, slicing extraction raw materials of plant extracts, pouring the slices into a wall breaking machine, breaking the wall at 8000r/min, crushing for 45min until the extraction raw materials are in a slurry state, and then performing crude extraction by using 75% ethanol, wherein the volume ratio of the ethanol to the slurry extraction raw materials is 1;
and A2, sequentially extracting the crude extract treated by the constant-temperature water bath at the constant temperature of 65 ℃, then combining the extract liquor after sequentially extracting by using ethyl acetate and n-butyl alcohol, and obtaining the plant extract (the ratio of the raw material to the extract is 10.
Table (b): raw material components of plant extract components of preparation examples 10 to 15 and weights (kg) thereof
Performance test
The peony collagen ginseng composite peptide solid beverage prepared in each example and comparative example was taken three times a day at 2 × 5g each time as a test subject, and the test subject was 75 men 25 to 30 years old with three high symptoms (three persons per group):
before the test, detecting the initial blood sugar (fasting condition), blood fat (triglyceride monoester is taken as an example) and blood pressure (highest systolic pressure value), and then testing the blood sugar, the blood fat and the blood pressure of the peony collagen ginseng compound peptide solid beverage for 30 days again on the 30 th day of continuously taking the peony collagen ginseng compound peptide solid beverage;
calculating the change rate delta E% by combining the initial blood sugar, blood fat and blood pressure;
Δ E% = (blood glucose, blood lipid and blood pressure of 30 d-initial blood glucose, blood lipid and blood pressure/initial blood glucose, blood lipid and blood pressure); the blood sugar, blood fat and blood pressure reducing effect is characterized by the change rate delta E% of the blood sugar, the blood fat and the blood pressure, the delta E is more than 30%, and the effect is regarded as remarkable and is marked as excellent; 30> Δ E >10%, and is marked as ≈ when considered as effective; 10> Δ E >, considered to be essentially negligible, is counted as x.
Examples
Examples 1 to 6
A peony collagen ginseng composite peptide solid beverage comprises a polypeptide composition and a solid beverage base formula, wherein the dosage of the polypeptide composition and the dosage of the solid beverage base formula are 1;
wherein the polypeptide composition is prepared in preparation example 1;
the solid beverage base formulation has the following components and their respective weights (per 100 kg);
and is prepared by the following preparation method:
s1, uniformly mixing each component in the raw materials with deionized water according to a weight percentage of 1;
s2, putting the mixed material liquid obtained in the step S1 into a spray freeze dryer, controlling the air inlet temperature to be 100 ℃ and the air inlet flow to be 260m 3 And h, controlling the air outlet temperature to be 80 ℃, thus obtaining the peony collagen ginseng composite peptide solid beverage.
The preparation method in the application only takes the above preferred conditions as an example, and other operation conditions can be adopted in other embodiments, and the condition change in the above range does not affect the actual properties of assisting in reducing blood fat, blood sugar and blood pressure, and only relates to the hardness, disintegration rate and water content of the final finished product.
Table: the components and their weights (kg) in examples 1-6
Comparative example 1
A solid beverage, which differs from example 1 in that the polypeptide composition is only a single polypeptide of peony oligopeptide.
Three test persons who took the solid beverages of examples 1 to 6 and comparative example 1 were each drawn, and then the rate of change Δ E% was determined from their initial blood glucose, blood lipid and blood pressure and from the blood glucose, blood lipid and blood pressure taken for 30 days continuously, and the average value was recorded in the following table.
Table (b): results of Performance test of examples 1 to 6 and comparative example 1
As can be seen from the table above, the peony collagen ginseng composite peptide solid beverage prepared in the examples 1-6 has excellent auxiliary blood sugar, blood fat and blood pressure reducing performance, and the change rate delta E of the blood sugar after the solid beverage is continuously taken for 30 days is 21.8-22.8%; the change rate delta E of the blood fat after 30 days is 32.5-33.8%; the change rate delta E of the blood pressure after 30 days is 22.8-23.8%
Therefore, the components in the used polypeptide composition can promote the secretion of thyroid hormone and insulin, inhibit the rise of cholesterol and regulate blood sugar through the characteristics of the polypeptide, thereby achieving the effects of assisting in reducing blood fat, reducing blood sugar and reducing blood pressure; the multi-component polypeptide composition can further improve the effects of reducing blood fat, blood sugar and blood pressure by compounding, and the analysis reason is that the multi-component compound composition can obviously improve the metabolic capability and the vascular toughness of the kidney of a human body, thereby creating an environment which is not beneficial to causing hypertension, hyperlipidemia and hyperglycemia.
In addition, the above table shows that the examples 1 to 6 are all preferred examples, the combination and compatibility of the solid beverage basic formula with different compositions and proportions and the polypeptide composition are both better, and the solid beverage basic formula can promote the penetration and diffusion of the polypeptide composition after being eaten, but the effects of actually assisting in reducing blood fat, blood sugar and blood pressure can be ignored.
Example 7
The difference between the peony collagen ginseng compound peptide solid beverage and the embodiment 1 is that the dosage of the polypeptide composition and the solid beverage base formula is 1.
Example 8
The difference between the peony collagen ginseng compound peptide solid beverage and the embodiment 1 is that the dosage of a polypeptide composition and a solid beverage base formula is 1.
Three persons were each taken from the test subjects who took the solid beverages of examples 7 to 8, and then the change rate Δ E% was determined from their initial blood sugar, blood fat and blood pressure and from the blood sugar, blood fat and blood pressure taken continuously for 30 days, and the average value was recorded in the following table.
Table: results of testing the Properties of examples 1, 7 to 8
As can be seen from the table above, the peony collagen ginseng compound peptide solid beverage prepared in the examples 1 and 7-8 has excellent auxiliary blood sugar, blood fat and blood pressure reducing performance, and the change rate delta E of the blood sugar after the peony collagen ginseng compound peptide solid beverage is continuously taken for 30 days is 21.8-24.5%; the change rate delta E of the blood fat after 30 days is 32.5-34.8%; the change rate delta E of the blood pressure after 30 days is 22.8-25.5%
It can be seen that the above-mentioned polypeptide compositions can achieve the effects of assisting in reducing blood lipid, reducing blood glucose and reducing blood pressure, but it can also be known from examples 1 and 7-8 that the auxiliary performance is relatively equivalent and no longer improved with the increase of the dosage of the polypeptide composition, so the dosage ratio of the solid beverage basic formula and the polypeptide composition with the optimized comprehensive cost and performance is 1 (0.1-0.5).
Examples 9 to 13
A peony collagen ginseng compound peptide solid beverage is different from that in example 1 in that the using conditions of the used polypeptide composition are different, and the specific corresponding relation is shown in the following table.
Table: EXAMPLES 9-13 use of polypeptide compositions
| Group of | Polypeptide compositions |
| Example 9 | Prepared from preparation example 2 |
| Example 10 | Prepared from preparation example 3 |
| Example 11 | Prepared from preparation example 4 |
| Example 12 | Prepared from preparation example 5 |
| Example 13 | Prepared from preparation example 6 |
Three persons were each taken from the test subjects who took the solid beverages of examples 9 to 13, and then the change rate Δ E% was determined from their initial blood sugar, blood fat and blood pressure and from the blood sugar, blood fat and blood pressure taken continuously for 30 days, and the average value was recorded in the following table.
Table (b): results of testing the Performance of examples 1, 9 to 13
As can be seen from the table above, the peony collagen ginseng composite peptide solid beverage prepared in the examples 1 and 9-13 has excellent auxiliary blood sugar, blood fat and blood pressure reducing performance, and the change rate delta E of the blood sugar after the solid beverage is continuously eaten for 30 days is 21.8-27.5%; the change rate delta E of the blood fat after 30 days is 32.5-36.2%; the change rate delta E of the blood pressure after 30 days is 22.8-26.1%;
therefore, the polypeptide composition with the components and the proportion can exert the effects of reducing blood fat, blood sugar and blood pressure by compounding multiple components, wherein the peony oligopeptide, the bovine bone collagen peptide and the ginseng peptide are necessary basic formulas, and the compounding of other components can further enhance the effects;
the reason for analyzing the polypeptide is probably that the polypeptide components can enter adrenal cortex and microvessels respectively, and the aim of improving the metabolic capability and the vascular toughness of human kidneys is fulfilled by dissolving intravascular microemboli, stimulating the adrenal cortex and improving the microcirculation system of the adrenal cortex.
It can be seen from the above table that the examples 11-13 are preferred examples, and when multi-component peony oligopeptide, bovine bone collagen peptide, ginseng peptide, corn stigma peptide, moringa oleifera leaf peptide, houttuynia cordata peptide, tea polypeptide and the like are used simultaneously, the effects of assisting in reducing blood fat, reducing blood sugar and reducing blood pressure are most remarkable.
In addition, the adopted polypeptide composition has excellent oxidation resistance, is easy to be absorbed by a human body, and is not easy to bring extra load to the human body, namely free radicals causing aging are not easy to generate due to stimulation when the polypeptide composition acts on blood vessels and kidneys.
Examples 14 to 16
A peony collagen ginseng compound peptide solid beverage is different from that in example 1 in that the using conditions of the used polypeptide composition are different, and the specific corresponding relation is shown in the following table.
Table: EXAMPLES 14-16 polypeptide compositions use
Three test persons who took the solid beverages of examples 14 to 16 were each drawn, and then the rate of change Δ E% was determined from their initial blood glucose, blood lipid and blood pressure and from the blood glucose, blood lipid and blood pressure taken for 30 days continuously, and the average value was recorded in the following table.
Table: results of testing the Performance of examples 1, 14 to 16
As can be seen from the table above, the peony collagen ginseng composite peptide solid beverage prepared in the examples 1 and 14-16 has excellent auxiliary blood sugar, blood fat and blood pressure reducing performance, and the change rate delta E of the blood sugar after the solid beverage is continuously taken for 30 days is 21.8-22.8%; the change rate delta E of the blood fat after 30 days is 32.5-33.2%; the change rate delta E of the blood pressure after 30 days is 22.8-23.2%;
therefore, the polypeptide composition extracted by the protease has high retention of active ingredients in the polypeptide composition, and also has excellent oxidation resistance, so that the polypeptide composition can achieve the effects of assisting in reducing blood sugar, blood pressure and blood fat after being taken, and the obtained polypeptide has the optimal effect when neutral protease and alkaline protease are used simultaneously.
Example 17
The peony collagen ginseng compound peptide solid beverage is characterized by further comprising plant extraction components, wherein the dosage of the plant extraction components and the basic formula of the solid beverage is 1.
Example 18
The peony collagen ginseng compound peptide solid beverage is characterized by further comprising plant extraction components, wherein the dosage of the plant extraction components and the basic formula of the solid beverage is 1.
Example 19
The peony collagen ginseng composite peptide solid beverage is characterized by further comprising plant extract components, wherein the dosage of the plant extract components and the solid beverage basic formula is 1.
Three persons were each taken from the test subjects who took the solid beverages of examples 17 to 19, and then the change rate Δ E% was determined from their initial blood sugar, blood fat and blood pressure and from the blood sugar, blood fat and blood pressure taken continuously for 30 days, and the average value was recorded in the following table.
Table: results of testing the Performance of examples 1, 17 to 19
As can be seen from the table above, the peony collagen ginseng composite peptide solid beverage prepared in the examples 1 and 17-19 has excellent auxiliary blood sugar, blood fat and blood pressure reducing performance, and the change rate delta E of the blood sugar after the solid beverage is continuously eaten for 30 days is 21.8-23.5%; the change rate delta E of the blood fat after 30 days is 32.5-33.5%; the change rate delta E of the blood pressure after 30 days is 22.8-24.5%
It can be seen that the addition of the plants in the above proportions can further promote the effects of assisting in reducing blood lipid, blood glucose and blood pressure, but from examples 1 and 17-19, it can be seen that the auxiliary performance is basically equal with the increase of the dosage of the plant extract, so the dosage ratio of the plant extract to the solid beverage basic formula with preferable comprehensive cost and performance is 1 (0.1-0.3).
Examples 20 to 24
A peony collagen ginseng compound peptide solid beverage is different from that in example 1 in that the using conditions of the used polypeptide composition are different, and the specific corresponding relation is shown in the following table.
Table (b): EXAMPLES 20-24 use of polypeptide compositions
| Group of | Polypeptide compositions |
| Example 20 | Prepared from preparation example 11 |
| Example 21 | Prepared from preparation example 12 |
| Example 22 | Prepared from preparation example 13 |
| Example 23 | Prepared from preparation 14 |
| Example 24 | Prepared from preparation example 15 |
Three test persons who took the solid beverages of examples 20 to 24 were each drawn, and then the rate of change Δ E% was determined from their initial blood glucose, blood lipid and blood pressure and from the blood glucose, blood lipid and blood pressure taken for 30 days continuously, and the average value was recorded in the following table.
Table: results of testing the Performance of examples 1, 20 to 24
As can be seen from the table above, the peony collagen ginseng composite peptide solid beverage prepared in the examples 1 and 20-24 has excellent auxiliary blood sugar, blood fat and blood pressure reducing performance, and the change rate delta E of the blood sugar after the solid beverage is continuously eaten for 30 days is 21.8-24.6%; the change rate delta E of the blood fat after 30 days is 32.5-34.8%; the change rate delta E of the blood pressure after 30 days is 22.8-24.6%;
therefore, the plant extract prepared from the raw materials can act on a human body to directly enhance the basic immunity of the human body, and can play long-acting and lasting effects of reducing blood pressure and protecting the blood vessels by acting on the heart and the blood vessels under the condition of being taken for 30 days; in addition, the effect after the use for 3 months is better according to the use condition feedback of the user, but the sampling and test difficulty is considered, and only 30d is taken as an example;
the adopted extraction raw materials are green and natural, and have excellent oxidation resistance, so that the extract is easy to be absorbed by a human body, is not easy to cause additional stimulation and load to the human body, and can supplement the polypeptide composition with short-time action.
The present embodiment is only for explaining the present application, and it is not limited to the present application, and those skilled in the art can make modifications of the present embodiment without inventive contribution as needed after reading the present specification, but all of them are protected by patent law within the scope of the claims of the present application.
Claims (8)
1. A peony collagen ginseng composite peptide solid beverage is characterized by comprising a polypeptide composition and a solid beverage basic formula;
the polypeptide composition is one or more of peony oligopeptide, bovine bone collagen peptide, ginseng peptide, corn stigma peptide, moringa oleifera leaf peptide, houttuynia cordata peptide and tea polypeptide.
2. The peony collagen ginseng composite peptide solid beverage as claimed in claim 1, wherein the dosage of the polypeptide composition and the solid beverage base formula is 1 (0.1-0.5) by weight;
the polypeptide composition comprises the following components in parts by weight:
5-8 parts of peony oligopeptide, 8-12 parts of bovine bone collagen peptide, 3-5 parts of ginseng peptide, 0-8 parts of corn stigma peptide, 0-3 parts of moringa oleifera leaf peptide, 0-3 parts of houttuynia cordata peptide and 0-15 parts of tea polypeptide.
3. The peony collagen ginseng composite peptide solid beverage as claimed in claim 2, wherein the extraction method of each component in the polypeptide composition is as follows:
a1, performing ball milling treatment on each polypeptide raw material to obtain a coarse material;
a2, placing the coarse material obtained in the step A1 in ethanol, adjusting the pH value of the solution to 7.0-7.5, adjusting the temperature to 48-52 ℃, and adding 0.2-0.5% of protease for enzymolysis for 2-3h;
and A3, finally, putting the enzymatic hydrolysate after the completion of the enzymolysis into boiling water for enzyme deactivation for 3-5min, then carrying out centrifugal treatment, and filtering and freeze-drying the obtained precipitate to obtain each component in the polypeptide composition.
4. The peony collagen ginseng composite peptide solid beverage as claimed in claim 3, wherein the protease is composed of neutral protease and alkaline protease in a weight ratio of 1 (0.1-0.2);
the enzyme activity of the neutral protease is 0.8AU/g;
the enzyme activity of the alkaline protease is 2.4AU/g.
5. The peony collagen ginseng composite peptide solid beverage according to claim 1, further comprising a plant extraction component, wherein the plant extraction component is prepared from one or more of winter jujube, rosa roxburghii tratt, dandelion, chrysanthemum and hawthorn.
6. The peony collagen ginseng composite peptide solid beverage as claimed in claim 5, wherein the dosage of the plant extract component and the solid beverage basic formula is 1 (0.1-0.3) by weight;
the preparation raw materials of the plant extraction component comprise the following components in parts by weight:
5-8 parts of winter jujube, 10-15 parts of roxburgh rose, 2-3 parts of dandelion, 1-2 parts of chrysanthemum and 5-8 parts of hawthorn.
7. The peony collagen ginseng composite peptide solid beverage according to claim 1, wherein the solid beverage base formula comprises the following components in percentage by weight:
1-10% of compound amino acid powder, 3-5% of sodium hyaluronate, 1-10% of taurine, 1-2% of L-lysine hydrochloride, 1-2% of glycine, 2-3% of stevioside, 20-30% of hydroxypropyl methyl cellulose and the balance egg yolk globulin powder.
8. The preparation method of the peony collagen ginseng composite peptide solid beverage is characterized by comprising the following specific steps:
s1, uniformly mixing the components in the raw materials with deionized water according to the weight percentage of 1 (3-5), heating to 50-60 ℃, and circularly homogenizing for 3-5 times to obtain mixed feed liquid;
and S2, putting the mixed liquid obtained in the step S1 into a spray freeze dryer, and controlling the air inlet temperature to be 100-120 ℃, the air inlet flow rate to be 240-280m & lt 3 & gt/h and the air outlet temperature to be 80-100 ℃ to obtain the peony collagen ginseng composite peptide solid beverage.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210968122.4A CN115299544B (en) | 2022-08-12 | 2022-08-12 | Peony collagen and ginseng compound peptide solid beverage and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210968122.4A CN115299544B (en) | 2022-08-12 | 2022-08-12 | Peony collagen and ginseng compound peptide solid beverage and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115299544A true CN115299544A (en) | 2022-11-08 |
| CN115299544B CN115299544B (en) | 2023-11-03 |
Family
ID=83862928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210968122.4A Active CN115299544B (en) | 2022-08-12 | 2022-08-12 | Peony collagen and ginseng compound peptide solid beverage and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115299544B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070197639A1 (en) * | 2004-06-03 | 2007-08-23 | Judith Fischer | Hepoxilins and modulators of ichthyin for treatment skin disorders |
| CN105669830A (en) * | 2015-12-15 | 2016-06-15 | 北京天肽生物科技有限公司 | Composite oligopeptide powder |
| CN107746427A (en) * | 2016-06-24 | 2018-03-02 | 沈阳兴齐眼药股份有限公司 | A kind of cyclic peptide compound and its preparation method and application |
| CN112438356A (en) * | 2019-08-29 | 2021-03-05 | 东北农业大学 | Multi-element compound peptide solid beverage and preparation method thereof |
| CN112772813A (en) * | 2020-02-05 | 2021-05-11 | 河北康平健康产业有限责任公司 | Compound peptide solid beverage capable of improving immunity and relieving fatigue and preparation method thereof |
| CN112795614A (en) * | 2021-04-07 | 2021-05-14 | 广东稳邦生物科技有限公司 | Composite polypeptide extract with blood glucose and lipid reducing activities and application thereof |
| CN113115884A (en) * | 2019-12-31 | 2021-07-16 | 中粮集团有限公司 | Composite peptide solid beverage and preparation method and application thereof |
| CN114271502A (en) * | 2021-12-31 | 2022-04-05 | 青岛琛蓝健康产业集团有限公司 | Clam peptide compound for protecting cardiovascular system and kidney and application thereof |
| CN114306579A (en) * | 2022-01-06 | 2022-04-12 | 山东御匾生物科技有限公司 | Special active small-molecule compound peptide preparation for repairing body functions and preparation method thereof |
-
2022
- 2022-08-12 CN CN202210968122.4A patent/CN115299544B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070197639A1 (en) * | 2004-06-03 | 2007-08-23 | Judith Fischer | Hepoxilins and modulators of ichthyin for treatment skin disorders |
| CN105669830A (en) * | 2015-12-15 | 2016-06-15 | 北京天肽生物科技有限公司 | Composite oligopeptide powder |
| CN107746427A (en) * | 2016-06-24 | 2018-03-02 | 沈阳兴齐眼药股份有限公司 | A kind of cyclic peptide compound and its preparation method and application |
| CN112438356A (en) * | 2019-08-29 | 2021-03-05 | 东北农业大学 | Multi-element compound peptide solid beverage and preparation method thereof |
| CN113115884A (en) * | 2019-12-31 | 2021-07-16 | 中粮集团有限公司 | Composite peptide solid beverage and preparation method and application thereof |
| CN112772813A (en) * | 2020-02-05 | 2021-05-11 | 河北康平健康产业有限责任公司 | Compound peptide solid beverage capable of improving immunity and relieving fatigue and preparation method thereof |
| CN112795614A (en) * | 2021-04-07 | 2021-05-14 | 广东稳邦生物科技有限公司 | Composite polypeptide extract with blood glucose and lipid reducing activities and application thereof |
| CN114271502A (en) * | 2021-12-31 | 2022-04-05 | 青岛琛蓝健康产业集团有限公司 | Clam peptide compound for protecting cardiovascular system and kidney and application thereof |
| CN114306579A (en) * | 2022-01-06 | 2022-04-12 | 山东御匾生物科技有限公司 | Special active small-molecule compound peptide preparation for repairing body functions and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115299544B (en) | 2023-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3141255B1 (en) | Memory improving composition, preparation method and use thereof | |
| CN102458434B (en) | Composition for increasing the bioavailability of saponin | |
| CN100563668C (en) | Use the gen-seng and the processing thereof of vinegar | |
| CN107467650A (en) | A kind of jujube colla corii asini cake and preparation method thereof | |
| CN111617231B (en) | Uric acid-reducing and gout-resisting composition as well as preparation method and application thereof | |
| CN102599322A (en) | Tablet candy suitable for children and manufacturing method thereof | |
| CN104473171A (en) | Cannabis sativa buccal tablet and preparation method thereof | |
| KR100611796B1 (en) | Cosmetic composition containing medicinal herbs called sipgeondaebodan and method for preparing the same | |
| KR101518391B1 (en) | plum vinegar manufacturing method | |
| KR102549413B1 (en) | Method for preparing a composition for treating hair loss | |
| WO2021078288A1 (en) | Activated insulin, compound momordica charantia peptide oral medicine for treatment of diabetes, and preparation method | |
| JP2000503535A (en) | Ginseng method and processed ginseng produced by it | |
| JP2015024982A (en) | Advanced glycation end products formation inhibitor | |
| CN115299544B (en) | Peony collagen and ginseng compound peptide solid beverage and preparation method thereof | |
| JP2001002583A (en) | Blood sugar level increase inhibitor | |
| CN111165709A (en) | Solid beverage with blood sugar control function and preparation method thereof | |
| CN109846038A (en) | A kind of lower hyperlipidemia, hypertension, hyperglycemia compound small-molecular peptides functional food and preparation method thereof | |
| KR100815197B1 (en) | The manufacturing method of raw wine containing ginseng | |
| CN115088849A (en) | Compound oligomeric donkey-hide gelatin peptide product for qi benefiting and blood nourishing comprehensive conditioning and preparation method thereof | |
| JP3208531B2 (en) | Cosmetics containing grape and ginseng browned compositions | |
| KR102356983B1 (en) | Manufacturing method of soymilk | |
| CN113616573A (en) | I type collagen production promoter | |
| CN113142495A (en) | Preparation method of functional compound mixing powder | |
| CN108524850A (en) | A kind of liquor preparation for enhancing immune prevention cardiovascular and cerebrovascular disease | |
| JP2014108931A (en) | Inhibitor of production of advanced glycation end product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |